Zymeworks (ZYME) has released an update.
Zymeworks Inc., a biotech firm specializing in cancer treatments, will present promising preclinical data on two antibody-drug conjugates, ZW220 and ZW251, at the upcoming EORTC-NCI-AACR Conference. These studies underscore the potential of ZW220 in treating non-small cell lung, ovarian, and uterine cancers, and ZW251 in hepatocellular carcinoma, supporting their progress towards IND filings set for 2025.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
